At a glance
A dual-receptor agonist studied in weight and glucose regulation.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The cited trials evaluate weight and metabolic endpoints over defined follow-up periods. Results depend on the population and trial regimen; other dual agonists are not interchangeable.[2][3][5]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Mazdutide.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 5 mg · 2 source tables
Standard / Gradual Titration (3.0 mL = ~1.67 mg/mL)
| Week | Weekly Dose | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 2.5 mg (2,500 mcg) | 150 units (1.50 mL) |
| Weeks 5–8+ | 5 mg (5,000 mcg) | 300 units (3.00 mL) |
Frequency: Inject once weekly subcutaneously. This schedule mirrors clinical trial protocols with gradual titration to improve tolerability.[1][2] The 3.0 mL dilution provides practical unit measurements for standard maintenance doses.
Advanced / High‑Dose Protocol (2.0 mL = 2.5 mg/mL)
| Week | Weekly Dose | Units (per injection) (mL) | Notes |
|---|---|---|---|
| Weeks 1–4 | 5 mg (5,000 mcg) | 200 units (2.00 mL) | 1 vial |
| Weeks 5–8 | 7.5 mg (7,500 mcg) | 300 units (3.00 mL) | 1.5 vials |
| Weeks 9–12+ | 10 mg (10,000 mcg) | 400 units (4.00 mL) | 2 vials; split into 2 injections |
Caution: High‑dose protocols (7.5–10 mg weekly) have been explored in phase 1b research but require careful monitoring and clinical oversight.[1] Doses above 6 mg increase the risk of gastrointestinal side effects. The 2.0 mL reconstitution provides higher concentration to reduce injection volume. For doses requiring >3.0 mL total volume, split into two separate injections at different sites. Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Additional schedule context & duration
Concise summary of the once‑weekly regimen.
- Goal: Support chronic weight management and metabolic improvement through dual GLP‑1/glucagon receptor activation.[2][3]
- Schedule: Once‑weekly subcutaneous injections for 8–12 weeks minimum (clinical trials ranged from 12–48 weeks).
- Dose Range: 2.5–6 mg weekly with gradual titration; advanced protocols may reach 10 mg.
- Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for standard dosing; 2.0 mL for higher concentrations if needed.
- Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); discard after 28 days.[7][9]
Suggested weekly titration approach.
- Start: 2.5 mg once weekly for first 4 weeks to establish tolerability.
- Increase: Advance to 5 mg weekly at week 5; maintain for remainder of protocol (weeks 5–12+).
- Frequency: Once per week (subcutaneous injection).
- Cycle Length: Minimum 8 weeks; clinical evidence supports 12–48 week protocols.
- Timing: Administer on the same day each week; rotate injection sites to avoid irritation.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl until dissolved (do not shake vigorously).
- Label with date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide stability and potency.
- Lyophilized: Store at −20 °C (−4 °F) or below in dry, dark conditions; protect from moisture.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use bacteriostatic water for multi‑dose stability.[9]
- Important: Do not freeze reconstituted solution; avoid freeze–thaw cycles which can denature the peptide.[7]
- Discard: Dispose of reconstituted vials after 28 days or if cloudiness/particulates appear.
Injection Technique
Subcutaneous injection guidance based on clinical best practices.[8][9]
- Clean the vial stopper and injection site with alcohol swabs; allow to air‑dry completely.
- Use aseptic technique: wipe stoppers, use sterile needles, and avoid touching needle tip.
- Pinch a skinfold and insert the needle at 45–90° into subcutaneous fatty tissue (not muscle).
- Do not aspirate for subcutaneous injections; inject slowly and steadily over 5–10 seconds.
- Withdraw needle and apply gentle pressure with a clean swab; do not rub vigorously.
- Rotate injection sites systematically: abdomen (at least 2 inches from navel), front/outer thighs, or outer upper arms.
- For volumes >3 mL, divide dose into two injections at separate sites for comfort and absorption.
Materials & quantity planning
Source materials checklist · 5 mg
Plan based on an 8–16 week weekly protocol with gradual titration to 5 mg maintenance.
-
Peptide Vials (Mazdutide, 5 mg each):
- 8 weeks ≈ 6 vials (Weeks 1–4: 2 vials; Weeks 5–8: 4 vials)
- 12 weeks ≈ 10 vials (Weeks 1–4: 2 vials; Weeks 5–12: 8 vials)
- 16 weeks ≈ 14 vials (Weeks 1–4: 2 vials; Weeks 5–16: 12 vials)
-
Insulin Syringes (U‑100, 1 mL or 3 mL capacity):
- Per week: 1 syringe (once‑weekly dosing)
- 8 weeks: 8 syringes
- 12 weeks: 12 syringes
- 16 weeks: 16 syringes
-
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for standard reconstitution.
- 8 weeks (6 vials): 18 mL → 2 × 10 mL bottles
- 12 weeks (10 vials): 30 mL → 3 × 10 mL bottles
- 16 weeks (14 vials): 42 mL → 5 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each week.
- Per week: 2 swabs
- 8 weeks: 16 swabs → recommend 1 × 100‑count box
- 12 weeks: 24 swabs → recommend 1 × 100‑count box
- 16 weeks: 32 swabs → recommend 1 × 100‑count box
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 5 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
Research publication
EClinicalMedicine (PubMed) — Phase 1b trial: Safety and efficacy of mazdutide 9–10 mg in Chinese adults with overweight/obesity (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 03
Research publication
New England Journal of Medicine — Phase 3 trial: Once‑weekly mazdutide in Chinese adults with obesity or overweight (48‑week results) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Research publication
Diabetes Care (PubMed) — Phase 2 trial: Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes (20‑week results) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 08
- 09
Public health resource
NCBI Bookshelf — Clinical procedures: Subcutaneous injections (best practices and site rotation) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.